For all the talk about new and better ways to engage, pharma still hasn't created an appreciably higher volume of satisfied — or informed — customers.
Drugmakers are proud of the patient service programs they've developed. Yet there remains a disconnect in the way information is communicated to HCPs.
The answer: it depends on what phase the trial is in.
Despite approvals of competing products from AbbVie, Merck, and Bristol-Myers Squibb, Gilead remains the market leader.
Patients are demanding more of their healthcare experience — and that includes from their healthcare providers, according to two new surveys.
Drugmakers and providers alike struggle to find the best tools, words, and technologies that will improve adherence rates among patients with chronic diseases.
Researchers still don't know why Americans who are prescribed a prescription drug to treat a chronic condition or disease so often fail to fill those prescriptions.
A WebMD survey finds that patients are more engaged when they share their own health with their doctors.
One pharmacy director would like to see a lot more comparative data about new therapies.
A new survey found that 34% of healthcare and pharma marketers say that the election of President Trump will not affect their marketing budgets.
Physicians do not like EHRs. That much is clear. But the vast majority have to use electronic record systems on a daily basis. What can pharma do to better give doctors what they want?
How pharma distributes information to doctors is changing as rapidly as how doctors prefer to receive and process such information
Here are 5 statistics about off-label promotion ahead of the FDA's public hearing this week.
Ad pushes behind brands like Gilead Sciences' hepatitis-C pill Harvoni and Allergan's IBS drug Viberzi buoyed med-surg outlays for the first six months of 2016. Cancer drugs once again were the hottest category.
The availability of online medical information is changing the way doctors share and receive information — both among themselves and with their patients.
Type 2 diabetes is on the rise, around the world. The IMS Institute for Healthcare Informatics breaks down diabetes prevalence in Brazil, Mexico, Saudi Arabia, the U.K., and the U.S.
Here, see side-by-side comparisons of the drugs spending on advertising, approval dates, and 2015 sales figures.
The FDA has approved two biosimilars, but questions remain about how quickly providers and patients in the U.S. will adopt them.
Companies spend $2 billion per year recruiting patients for clinical trials. A survey of 702 adults, conducted from December 2015 to January 2016, points to a need for more awareness.
Finn Partners surveyed 1,000 adults to understand how often young Americans change doctors and how they talk to pharmacists.
Click for an infographic to learn more about orphan drugs, rare diseases and the top-selling drugs in the category.